tbuckley/cabot-search huggingface dataset:
Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Authors: Akshay S. Desai, Pardeep S. Jhund, Muthiah Vaduganathan, Brian L. Claggett, Jonathan W. Cunningham, Maria A. Pabon, Carolyn S. P. Lam, Michele Senni, Sanjiv Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Flaviana Amarante, James Lay-Flurrie, Markus F. Scheerer, Andrea Lage, John J. V. McMurray, Scott D. Solomon
Journal: JAMA Cardiology (2025)

Importance The mode of death in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) remains poorly understood and may vary by EF. Objective To evaluate the mode of death according to EF and the treatment effect of finerenone on cause-specific mortality in patients with HFmrEF/HFpEF. Design, Setting, and Participants This was a prespecified secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial, which evaluated clinical outcomes in 6001 patients with HF and EF greater than or equal to 40% randomly assigned to finerenone or placebo. The mode of death in relation to baseline EF categories (&amp;amp;lt;50%, ≥50-&amp;amp;lt;60%, and ≥60%) was examined, and the effect of randomized treatment on cause-specific death in Cox regression models was assessed. Data analysis was conducted between September 2024 and January 2025. Interventions Finerenone vs placebo. Main Outcomes and Measures Mode of death as centrally adjudicated by a clinical end points committee. Results Of 1013 patients (16.9%; median [IQR] age, 76 [69-82] years; 594 male [58.6%]) who died during median (IQR) follow-up of 32 (23-36) months, mode of death was ascribed to cardiovascular causes in 502 (49.6%), noncardiovascular causes in 368 (36.3%), and undetermined cause in 143 (14.1%). Of cardiovascular deaths, 215 (42.8%) were due to sudden death, 163 (32.4%) to HF, 48 (9.6%) to stroke, 25 (5.0%) to myocardial infarction, and 51 (10.2%) to other cardiovascular causes. The proportion of all-cause, cardiovascular, and sudden death was higher in those with EF less than 50%. The proportion of deaths related to HF was similar across EF categories, and the proportion of deaths due to myocardial infarction, stroke, and other cardiovascular causes was low regardless of EF. Randomization to finerenone did not significantly reduce death or cause-specific death compared with placebo in any EF category. Conclusions and Relevance Among patients with HFmrEF/HFpEF in the FINEARTS-HF randomized clinical trial, higher proportions of cardiovascular and overall mortality in those with EF less than 50% were related principally to higher proportions of sudden death. A clear treatment effect of finerenone on cardiovascular or cause-specific mortality was not identified, although the trial was likely underpowered for these outcomes. Trial Registration ClinicalTrials.gov Identifier: NCT04435626
HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE
Authors: Malek Alaiwah, Omar Alqaisi, Munes Albadaineh, Landon Bruich, Omar Darwish, Robert Spraggins, Brett Haley, Jackson Mosley, Ryan Harpenau, Ryan Pohlkamp, Alex Clausen, Noah Ross, Munthir Mansour, Srikanth Vallurupalli
Journal: Journal of the American College of Cardiology (2025)
ACUTE PERICARDITIS-RELATED MORTALITY TRENDS: GENDER AND GEOGRAPHIC DISPARITIES IN THE UNITED STATES OVER TWO DECADES
Authors: Jawad Basit, Shahzaib Ahmed, Eeman Ahmad, Prakash Upreti, chmsalddin alkhas, Mohammad Hamza, Farah Yasmin, M. Chadi Alraies
Journal: Journal of the American College of Cardiology (2025)
RETHINKING RISKS: CANNABIS USE AND ITS SURPRISING EFFECTS ON CARDIOVASCULAR DISEASE—A PROPENSITY SCORE MATCHED ANALYSIS USING THE NATIONAL INPATIENT SAMPLE (2017-2021)
Authors: Viet Nghi Tran, Doan Ngoc Chau Nguyen, Ayat Alhakeem, THANH HOANG, Aliza Khatiwada, Huan Dat Pham, Amreen Dhindsa, David Pielykh, Maja Boshkovska Spaseski, Danish Waqar, Vien T. Truong
Journal: Journal of the American College of Cardiology (2025)
ASSOCIATION BETWEEN DEPRESSION AND ENDOTHELIAL DYSFUNCTION IN MEDICAL STUDENTS
Authors: Isadora de Sá Guimarães, Pedro Bastos De Medeiros, ANDRE CASARSA MARQUES, Kelen Cruz, Julio Tolentino, Leticia Silva Flôr dos Santos, Matheus Nakazato Tinoco, SERGIO SCHMIDT
Journal: Journal of the American College of Cardiology (2025)
DEVELOPMENT AND VALIDATION OF PERSONALIZED RISK ESTIMATION WITH CLINICAL AND INTEGRATED SOCIO-ENVIRONMENTAL DATA FOR DIABETES MELLITUS (PRECISE-DM): A MULTIMODAL PREDICTION TOOL FROM THE HOUSTON METHODIST CARDIOVASCULAR LEARNING HEALTH SYSTEM REGISTRY
Authors: Sadeer G. Al-Kindi, Budhaditya Bose, Rakesh Gullapelli, Juan Nicolas, Kershaw Patel, Eleonora Avenatti, Archana Sadhu, Bobak Mortazavi, Jay Maddock, Amy Waterman, Ashutosh Sabharwal, Haider Warraich, Stephen Jones, Khurram Nasir
Journal: Journal of the American College of Cardiology (2025)
EFFICACY AND SAFETY OF BEMPEDOIC ACID FOR LDL-C REDUCTION IN STATIN-INTOLERANT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Muhammad Adil Afzal, Muhammad Abdullah, Noman Khalid, Mubariz Ahmed Hassan, Yezin F. Shamoon, Muhammad Atif M. Noori, Salman M. Muddassir, Rahul Vasudev, Fayez E. Shamoon
Journal: Journal of the American College of Cardiology (2025)
SUDDEN CARDIAC DEATH IN OLDER ADULTS: GEOGRAPHIC, GENDER, AND RACIAL TRENDS IN THE UNITED STATES (1999-2020)
Authors: Mobeen Z. Haider, Muhammad Abdullah Naveed, Ahila Ali, Muhammad Omer Rehan, Rabia Iqbal, Faizan Ahmed, Mayank Jha, Muhammad Aamir, M. Chadi Alraies, Apurva Vijay Vyas
Journal: Journal of the American College of Cardiology (2025)
ASSOCIATION BETWEEN SODIUM INTAKE AND HYPERTENSION AND OTHER CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW OF THE LITERATURE
Authors: Caroleen Drachenberg, Sumeet Attri, Gunjan Bisht, Barinder Singh, Sam Mettam, Hema N. Viswanathan, Shawn Candler, Jessica K. Alexander, Lee A. Surkin
Journal: Journal of the American College of Cardiology (2025)
A REAL-WORLD EVALUATION OF SACUBITRIL/VALSARTAN IN ACUTE MYOCARDIAL INFARCTION PATIENTS WITH HIGH CHARLSON COMORBIDITY INDEX
Authors: hongya liu, Yukun Zhang, Sutao Hu, Tianshu Gu, Jingkun Zhang, Xue Wu, Xing Liu, Xian Shao, LIN WANG, Jinhua Zhao, Tong Liu, Kang-Yin Chen
Journal: Journal of the American College of Cardiology (2025)
Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation
Authors: Rajesh K Kharbanda, James Kennedy, Zahra Jamal, Matthew Dodd, Richard Evans, Kiran K Bal, Alexander D Perkins, Daniel J Blackman, David Hildick-Smith, Adrian P Banning, Andreas Baumbach, Peter Ludman, Stephen Palmer, Rodney H Stables, Robert Henderson, Clare Appleby, James Cotton, Nick Curzen, Muhiddin Ozkor, Jonathan Byrne, Rajesh Aggarwal, Rajiv Das, Sagar Doshi, Stuart Watkins, Douglas F Muir, Richard Anderson, Saqib Chowdhary, Richard Varcoe, Stephen Dorman, Sam Firoozi, Raj Chelliah, Colum Owens, Simon Redwood, Bernard Prendergast, Javaid Iqbal, Karim Ratib, Ciprian Dospinescu, Venkatesan Suresh, Nicholas Cruden, Thirumaran Rajathurai, Iqbal S Malik, Andrew Wiper, Charis Costopoulos, Ayush Khurana, Amerjeet Banning, Tim Clayton
Journal: New England Journal of Medicine (2025)

Transcatheter aortic-valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection (CEP) devices may reduce embolization to the cerebral circulation and hence the incidence of stroke. We conducted a randomized, controlled trial across 33 centers in the United Kingdom. We randomly assigned 7635 participants with aortic stenosis in a 1:1 ratio to undergo TAVI with a CEP device (CEP group) or TAVI without a CEP device (control group). The primary outcome was stroke within 72 hours after TAVI or before discharge from the hospital (if discharge occurred sooner). A total of 3815 participants were assigned to the CEP group and 3820 to the control group. A primary-outcome event occurred in 81 of 3795 participants (2.1%) in the CEP group and in 82 of 3799 participants (2.2%) in the control group (difference, -0.02 percentage points; 95% confidence interval, -0.68 to 0.63; P = 0.94). Disabling stroke occurred in 47 participants (1.2%) in the CEP group and in 53 (1.4%) in the control group. Death occurred in 29 participants (0.8%) in the CEP group and in 26 (0.7%) in the control group. Overall access-site complications appeared to be similar in the two groups (8.1% in the CEP group and 7.7% in the control group). A total of 24 serious adverse events occurred in 22 of 3798 participants (0.6%) in the CEP group, and 13 serious adverse events occurred in 13 of 3803 participants (0.3%) in the control group. Among participants undergoing TAVI, routine use of CEP did not decrease the incidence of stroke within 72 hours. (Funded by the British Heart Foundation and Boston Scientific; BHF PROTECT-TAVI ISRCTN Registry number, ISRCTN16665769.).
THROWN FOR A LOOP: LUPUS INDUCED HEART FAILURE IN THE SETTING OF ALCOHOL WITHDRAWAL
Authors: Navid Radfar, Thomas Lee, Brian Smighelschi, Tyler Soobryan, Nicholas Lepore, Joseph Perona, Emaad Siddiqui, Afif Hossain, Eugenio Capitle, Joseph Allencherril
Journal: Journal of the American College of Cardiology (2025)
Two-year Outcomes of Transcatheter Edge-to-edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Trial
Authors: Saibal Kar, Raj R. Makkar, Brian K. Whisenant, Nadira Hamid, Hursh Naik, Peter Tadros, Matthew J. Price, Gagan Singh, Jonathan G. Schwartz, Samir Kapadia, Oluseun Alli, Samuel Horr, Puvi Seshiah, Wayne Batchelor, Brandon M. Jones, Mustafa I. Ahmed, Raymond Benza, Ulrich Jorde, Vinod H. Thourani, Andrew A. Ghobrial, Gilbert H.L. Tang, Phillip M. Trusty, Dina Huang, Rebecca T. Hahn, David H. Adams, Paul Sorajja
Journal: Circulation (2025)

Background: One-year outcomes of the TRILUMINATE Pivotal trial found that transcatheter edge-to-edge repair (TEER) for the treatment of severe, symptomatic tricuspid regurgitation (TR) improved quality-of-life compared with medical therapy alone with similar rates of mortality and heart failure hospitalization (HFH). However, additional follow-up is necessary to determine prolonged benefits of tricuspid TEER. Methods: A total of 572 patients with severe, symptomatic TR were randomized to either tricuspid TEER+medical therapy (Device) or medical therapy alone (Control). Two-year prespecified endpoints were (1) recurrent HFH and (2) freedom from all-cause mortality, tricuspid valve surgery and tricuspid valve intervention post treatment visit, assessed in the intention-to-treat population. Results: The annualized rate of recurrent heart failure hospitalizations through 2 years was significantly lower with tricuspid TEER compared with Control (0.19 vs 0.26 events/patient-year, p=0.02; joint frailty model hazard ratio 0.72, one-sided upper confidence limit of 0.93, p=0.02). Freedom from all-cause mortality, tricuspid valve surgery, and tricuspid valve intervention through 2 years was significantly higher with tricuspid TEER compared with Control (77.6% vs 29.3%, p&lt;0.0001) driven by more tricuspid valve intervention in control patients crossing over to device treatment (3.8% vs. 61.5%). Rates of all-cause mortality (17.9% vs. 17.1%) and tricuspid valve surgery (2.3% vs. 4.3%) were similar between groups. Moderate-or-less TR was present in 84% at 2 years in the Device group. Conclusions: At 2-year follow-up, tricuspid TEER appears safe, significantly reduced TR severity, and decreased rates of HFH compared with medical therapy alone.
RESCUE TAP (T AND SMALL PROTRUSION) BIFURCATION PCI FOR LEFT CIRCUMFLEX INJURY AFTER MITRAL VALVE ANNULOPLASTY AND LEFT ATRIAL APPENDAGE EXCISION
Authors: Hanyuan Shi, Max Biondi, Augustin DeLago, Athos J. Rassias, James T. DeVries
Journal: Journal of the American College of Cardiology (2025)
LEFT ATRIAL SEPTAL POUCH THROMBUS PROHIBITING TRANS-SEPTAL PUNCTURE FOR LEFT ATRIAL APPENDAGE CLOSURE - FAILING TO PLAN IS PLANNING TO FAIL
Authors: Ramy Abdelmaseih, Dallin Swanson, Mustajab Hasan, Umamahesh C. Rangasetty
Journal: Journal of the American College of Cardiology (2025)
ATRIAL APPENDAGE CLOSURE DEVICE ALERT! CLOT AHEAD AT 5 O’CLOCK
Authors: Maliha Butt, Husban Halim, Anas Alameh, Bala Pushparaji, Maxine Nelson, Mohammed Faisaluddin, Aleksandr Rovner, Robert S. Finkelhor
Journal: Journal of the American College of Cardiology (2025)
A SHOCKING TURN: DELAYED PRESENTATION OF CARDIOVERSION-INDUCED TAKOTSUBO SYNDROME WITH VENTRICULAR FIBRILLATION ARREST
Authors: Akanksha Maurya, Sina Bagheri, Sina Bakhshaei, Collin Jacobsen, Kaitlyn Ghassemi, Armin Hojjat, Andrew Ho
Journal: Journal of the American College of Cardiology (2025)
VALVE-IN-VALVE TRANSCATHETER MITRAL VALVE REPLACEMENT FOR SEVERE BIOPROSTHETIC MITRAL VALVE STENOSIS WITH SUPRASYSTEMIC PULMONARY HYPERTENSION
Authors: Akshitha Yarrabothula, Ken Chan, Maria Jamilla Lacap, Poyee Tung, Abhijeet Dhoble
Journal: Journal of the American College of Cardiology (2025)
INFECTED CARDIAC MYXOMA COMPLICATED BY INFECTIVE ENDOCARDITIS AND SEVERE MITRAL REGURGITATION
Authors: Zan Siddiqi, Karuna Rayamajhi, Amey Joshi, Kevin Watat, Maitri Shah, Sai Sushrutha Mudupula Vemula, Qi Xuan Ang, Lalitsiri Atti, Adolfo Martinez, Majid Yavari, Michael Kehdi, Hisham Qandeel
Journal: Journal of the American College of Cardiology (2025)
LEFT ATRIAL MURAL INFECTIVE ENDOCARDITIS WITH ENTEROCOCCUS FAECALIS; VALVE IS NOT ALWAYS THE CULPRIT
Authors: Anjelika Evangelopoulos, Pouyan Razminia, Amir Singh, Mark Kosinski, Alejandra Diaz Sierra, Alfredo Toll, Abdulkareem Opeoluwa Lukan, Pedro A. Gonzalez
Journal: Journal of the American College of Cardiology (2025)
CARDIAC RESYNCHRONIZATION THERAPY AS SALVAGE THERAPY IN A CRITICALLY ILL PATIENT WITH HEART FAILURE AND CARDIOGENIC SHOCK
Authors: Maria del Mar Burgos, Luis Alejandro Molinary-Jimenez, Porfirio E. Diaz-Rodriguez, Victor H. Molina-Lopez, Juan J. Rivera Torres, Francisco J. Cordova
Journal: Journal of the American College of Cardiology (2025)
TWO RARE CASES OF COMBINED LEFT VENTRICULAR NON-COMPACTION AND APICAL HYPERTROPHY
Authors: Suman Paudel, Dhan Shrestha, George O. Angheloiu, Shwetha Gopal, Abolfazl Ahmady, Roudabeh Kiani, Kannate Chotiphansiri, Mohamed Abugrin
Journal: Journal of the American College of Cardiology (2025)
ACUTE STRESS CARDIOMYOPATHY PRECIPITATED BY HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS REQUIRING MECHANICAL SUPPORT: A RARE PRESENTATION AND PREVIOUSLY UNREPORTED APPROACH TO MANAGEMENT
Authors: Elizabeth Ghandakly, Ahmad Gharaibeh, Jonathan Labin, Andrew Abboud, Heya Batah, Venu Menon
Journal: Journal of the American College of Cardiology (2025)
IMATINIB-INDUCED SEROSITIS: A CASE OF PERICARDIAL EFFUSION AND BILATERAL PLEURAL EFFUSION
Authors: Pallab Sarker, Muhammad Mohsin Zafar, Muhammad Umer Riaz Gondal, Shabab Chowdhury, utsow saha, Hassam Saif
Journal: Journal of the American College of Cardiology (2025)
A RARE CASE OF GLYCOPYRROLATE INDUCED BIVENTRICULAR TAKOTSUBO CARDIOMYOPATHY
Authors: Nishita Vattem, Rahul Patel, Andrew Mariano, Dureshahwar Ali, Dhruv Joshi, Vikas Patel, Abhimanyu Beri, Nha Huynh, Tarun Jain, Vivek Reddy
Journal: Journal of the American College of Cardiology (2025)
BATTLING CRITICAL DECISIONS: AMLODIPINE TOXICITY, HIGH-OUTPUT HEART FAILURE, VASOPLEGIA, AND ECMO SUPPORT
Authors: Amal Benchakroun, Harrison Koss, Leonard F. Efuet-Ateh, Sajid Mirza, Sunil Bali, Waqas S. Ghumman
Journal: Journal of the American College of Cardiology (2025)
PERICARDIAL CYST: A RARITY BEHIND CHEST PAIN
Authors: Ramón Angel Soto Rodríguez, Raúl Emmanuel Fonseca Robles, Axel Rodriguez Mendez, Javier Solis Estrada, Gabriela Paola Alanis Estrada, Mario Andrés De Jesús Leal Villarreal, Lisseth Hernandez Gonzalez, Daniel Manzur Sandoval
Journal: Journal of the American College of Cardiology (2025)
HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY UNMASKED BY ALCOHOL: A DIAGNOSTIC CHALLENGE IN ACUTE INTOXICATION
Authors: Rita N. Offor, Ekenedilichukwu Nnadi, Maureen Masara, Abena Korwaa Agyekum, Stefanie Clinton Fotso Simo, bisrat nigussie, Suzette B. Graham-Hill
Journal: Journal of the American College of Cardiology (2025)
A RARE INSTANCE OF PULMONARY HYPERTENSION PREVENTING CARDIAC TAMPONADE IN A PATIENT WITH MYOPERICARDITIS ASSOCIATED WITH LARGE PERICARDIAL EFFUSION
Authors: Dheeraj Pinninty, Balaphanidhar Mogga, VINEETH KANIPAKAM REDDY, Reethika G, Shriya Rajashekar, Eman Rashed, Rany Saleh
Journal: Journal of the American College of Cardiology (2025)
FIRST REPORTED CASE OF METASTATIC GASTRIC GLOMUS TUMOR COMPLICATED WITH COVERING THROMBOTIC TISSUE MIGRATING TO THE RIGHT ATRIUM
Authors: Ankit Hanmandlu, Anisha Pareddy, Amrit Kanwar, Amro Alhouda, Fadi Kathawa, Varun Nandamudi, Aveen Salar, Bourann Husainy, Carlos Oviedo
Journal: Journal of the American College of Cardiology (2025)
UNCOVERING ISOELECTRIC PREMATURE VENTRICULAR CONTRACTIONS WITH CONTINUOUS MONITORING VIA APPLE WATCH
Authors: Eli Herink, Aashish Katapadi, Douglas Darden, Naga Venkata K. Pothineni, Rajesh Kabra, Rakesh Gopinathannair, Dhanunjaya R. Lakkireddy
Journal: Journal of the American College of Cardiology (2025)
A HIDDEN TRIGGER: CORONARY VASOSPASM AND VENTRICULAR FIBRILLATION IN A PATIENT WITH RAYNAUD’S PHENOMENON
Authors: Agara Srinivasa Gagan Kumar, Sadiya Thermidor, Felix Adrian Valverde, Noor Alsammarraie, Manya Kumar, Daniel Jimenez Corado, Michael A. Logue
Journal: Journal of the American College of Cardiology (2025)
INCOMPLETE LEFT ATRIAL APPENDAGE OCCLUSION DUE TO CHALLENGING ANATOMY
Authors: Vincenzo Mirco La Fazia, Carola Gianni, Sanghamitra Mohanty, Mohamed Bassiouny, Weeranun Dechyapirom Bode, John D. Burkhardt, Luigi Di Biase, Amin Al-Ahmad, Rodney P. Horton, Andrea Natale
Journal: Journal of the American College of Cardiology (2025)
QUICK THINKING: EMERGENT TAVI FOR ACUTE BIOPROSTHETIC AORTIC REGURGITATION
Authors: Joseph Adams, Danny Cho, Viktoriya Bikeyeva, Chad V. Morreale, Shoeb Mohammed Hussain, Homam Ibrahim, Neal Narain Sawlani, Adib M. Chaus
Journal: Journal of the American College of Cardiology (2025)
RARE BUT DEADLY: RIGHT VENTRICULAR MYXOMA OBSTRUCTING THE RVOT—A CARDIAC EMERGENCY
Authors: HILLARIE RIOS, Andres Garcia Berrios, Maria Alejandra Rodriguez-Santiago, Gabriel Perez Cordero, Jose Maldonado, Marcel A. Mesa-Pabon, Pedro Enrique Vargas Otero
Journal: Journal of the American College of Cardiology (2025)
PERICARDIAL SPILL WITH CARDIAC TAPPONAGE SECONDARY TO PLEURAL TUBERCULOSIS
Authors: Nelson Acosta, Edgar D. Cadena Barranco, Cleysi Galva, Luz Del Alba Javier, Wilnelia Acosta, Ernesto Diaz Alvarez, ROSA GENESIS MEJIA MARTE
Journal: Journal of the American College of Cardiology (2025)
ACUTE RCA INFARCT LEADING TO SEVERE MITRAL REGURGITATION AND RV DYSFUNCTION: A CASE OF REMARKABLE RECOVERY AFTER CORONARY STENTING
Authors: John Abdelnour, Firas Anaya, Anas Alameh, Swasti Mehta, Ewa Wypasek, Aisha Siraj
Journal: Journal of the American College of Cardiology (2025)
UNVEILING LIGHT CHAIN CARDIAC AMYLOIDOSIS: THE ROLE OF TIMELY ENDOMYOCARDIAL BIOPSY IN EARLY LIGHT CHAIN DISEASE
Authors: Mohammed Faisaluddin, Anas Alameh, Fares Sukhon, Maliha Butt, Ahmad Jabri, Phoo Pwint Nandar
Journal: Journal of the American College of Cardiology (2025)
UNUSUAL CASE OF DOUBLE WHAMMY- VENTRICULAR FIBRILLATION &amp; STEMI
Authors: Niravkumar Patel, Lalith Namburu, Sai Karthik Kommineni, Manar H. Jbara, jeetendra b. patel, Vijay K. Ramu
Journal: Journal of the American College of Cardiology (2025)
A FLUTTERING HEART: UNRAVELING THE MYSTERY OF MYXOMA AND LIPOMA IN ATRIAL FLUTTER
Authors: Anjelika Evangelopoulos, Amir Singh, Pouyan Razminia, Mark Kosinski, Alejandra Diaz Sierra, Alfredo Toll, Abdulkareem Opeoluwa Lukan, Pedro A. Gonzalez
Journal: Journal of the American College of Cardiology (2025)
MULTIMODALITY IMAGING APPROACH FOR A TRANSIENT ISCHEMIC STROKE AS A FIRST MANIFESTATION OF PAPILLARY FIBROELASTOMA
Authors: Mariana Garcia, Daniel Sierra, Diego Araiza Garaygordobil, Rodrigo Gopar-Nieto, Raul Rodrigo Neri-Bale, Jorge Cuellar, Brenda Domínguez Garcidueñas, Anna Elisa Adib Gracia, Alexandra Arias-Mendoza
Journal: Journal of the American College of Cardiology (2025)
COMPLEX CASE OF VT STORM IN LVAD
Authors: Safwan Gaznabi, Jeirym Miranda, Ola Abdelkarim, Annalisa Filtz, Daniel Lorenzatti, David Mintz, Jooyoung Julia Shin, Justin Johannesen, Aldo L. Schenone, Ulrich P. Jorde, Mario J. Garcia, Leandro Slipczuk, Carlos A. Gongora
Journal: Journal of the American College of Cardiology (2025)
Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: a Randomized Clinical Trial
Authors: Varsha Keelara Tanguturi, Roukoz Abou-Karam, Fangzhou Cheng, Rong Duan, Ignacio Inglessis, Nathaniel Langer, Evin Yucel, Jonathan Passeri, Judy Hung, Sammy Elmariah
Journal: Circulation (2025)

Background: Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of transcatheter therapies. We evaluate the impact of electronic provider notifications (EPN) on rates of AVR at 1-year. Methods: In a pragmatic cluster randomized clinical trial conducted within multicenter academic health system from March 2022 through November 2023, 285 providers who had ordered a transthoracic echocardiogram (TTE) with findings potentially indicative of severe AS with aortic valve area ≤ 1.0 cm 2 were enrolled. Providers were randomly assigned to receive EPN for each of their patients with severe AS on TTE or to usual care. Notifications highlighted the detection of severe AS and included patient-specific clinical guideline recommendations for its management. The primary endpoint was the proportion of patients with severe AS receiving AVR within 1-year of the index TTE. Results: A total of 144 providers were randomized to intervention and 141 to control, resulting in 496 and 443 patients assigned to each group, respectively. The patient cohort had mean age of 77±11 years, was 47% female, and had mean aortic valve area 0.8±0.1 cm 2 . Rates of AVR within 1-year were 48.2% with EPN versus 37.2% with usual care (OR 1.62; 95% CI 1.13-2.32; p=0.009) and 60.7% and 46.5%, respectively, amongst symptomatic patients (OR 1.77; 95% CI 1.17-2.65; p=0.006). Notification treatment effect was highest with EPN in patients &gt;80 years of age (OR 2.00; 95% CI 1.17-3.41; p=0.01), in women (OR 2.78; 95% CI 1.69-4.57; p&lt;0.001), and when index TTE was performed within the inpatient setting (OR 2.49, 95% CI 1.44-4.31; p&lt;0.001). Within 1-year, restricted mean survival time was longer with EPN in all (12 days; p=0.04) and symptomatic patients (23 days; p=0.01). Conclusions: In this first study of EPN in valvular heart disease, EPN increased rates of AVR for severe AS, lessened gender and age disparities in AVR utilization, and improved survival time. EPN may provide a simple, scalable intervention to raise awareness of critical TTE findings and improve the quality of care for severe AS.